Breaking News Instant updates and real-time market news.

VOYA

Voya Financial

$43.69 /

-0.49 (-1.11%)

16:22
05/05/20
05/05
16:22
05/05/20
16:22

Voya Financial says outlook will be affected by COVID-19 uncertainties

"Looking ahead, we expect that our earnings growth outlook - as with others in the industry - will be affected by the uncertainties created by COVID-19, such as the magnitude of claims, changes to employment levels, and the ultimate shape of a future economic recovery. This uncertainty makes it very difficult to confidently provide medium and long-term earnings growth guidance. We will revisit our earnings growth guidance ranges, including the previously shared $1.80 to $1.90 EPS guidance for the fourth quarter 2021, as we gain improved visibility. Having said that, we will continue to execute on what we can control. For example, our targeted cost savings of at least $250 million by the end of 2020 remain on track, as is the expected closing of the sale of our Individual Life and other legacy non-retirement annuities businesses by Sept. 30, 2020. I'm confident in the talent that we have at Voya to enable us to execute on our organic growth, cost savings, and capital management plans to ensure that we can continue to position Voya for long-term success," added Martin.

  • 06

    May

  • 21

    May

  • 21

    May

VOYA Voya Financial
$43.69 /

-0.49 (-1.11%)

04/07/20 JPMorgan
Voya Financial upgraded to Neutral on lower risk profile at JPMorgan
04/07/20 JPMorgan
Voya Financial upgraded to Neutral from Underweight at JPMorgan
03/20/20 RBC Capital
Voya Financial price target lowered to $60 from $72 at RBC Capital
03/20/20 RBC Capital
RBC Capital sees some time before Life Insurance returns to 'normal'

TODAY'S FREE FLY STORIES

Hot Stocks
Fly Intel: Top five weekend stock stories » 19:58
05/25/20
05/25
19:58
05/25/20
19:58
HTZ

Hertz

$2.84 /

-0.215 (-7.04%)

, REGN

Regeneron

$569.94 /

+8.55 (+1.52%)

, SNY

Sanofi

$47.31 /

-0.18 (-0.38%)

, AMZN

Amazon.com

$2,435.90 /

-11.65 (-0.48%)

, WMT

Walmart

$124.32 /

-0.64 (-0.51%)

, NVAX

Novavax

$46.14 /

-3.975 (-7.93%)

, WGO

Winnebago

$58.06 /

+0.47 (+0.82%)

, POOL

Pool Corp.

$238.08 /

-0.32 (-0.13%)

, YETI

Yeti

$30.41 /

+0.38 (+1.27%)

, DBX

Dropbox

$21.67 /

-0.465 (-2.10%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Hertz Global (HTZ) has announced that it and certain of its U.S. and Canadian subsidiaries have filed voluntary petitions for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. "The impact of COVID-19 on travel demand was sudden and dramatic, causing an abrupt decline in the Company's revenue and future bookings. Hertz took immediate actions to prioritize the health and safety of employees and customers, eliminate all non-essential spending and preserve liquidity. However, uncertainty remains as to when revenue will return and when the used-car market will fully re-open for sales, which necessitated today's action. The financial reorganization will provide Hertz a path toward a more robust financial structure that best positions the Company for the future as it navigates what could be a prolonged travel and overall global economic recovery," the company said in a statement. Hertz's principal international operating regions including Europe, Australia and New Zealand are not included in the U.S. Chapter 11 proceedings. In addition, Hertz's franchised locations, which are not owned by the company, also are not included in the Chapter 11 proceedings. 2. Regeneron Pharmaceuticals (REGN) announced the commencement of an underwritten public secondary offering of its common stock through which Sanofi (SNY) intends to exit its investment in Regeneron shares. The shares being offered by Sanofi will be sold in an underwritten public offering. Sanofi currently owns approximately 23.2M Regeneron shares and intends to sell approximately 12.8M shares in the public offering. Sanofi also expects to grant the underwriters a 30-day option to purchase an additional 10% of the shares offered in the base offering. The registered offering and share repurchase will have no impact on the ongoing collaboration between Regeneron and Sanofi. Regeneron also announced that subject to and immediately following the close of the secondary offering, Regeneron agreed to repurchase approximately $5B of common stock directly from Sanofi. The purchase price to be paid by Regeneron will be equal to the net offering price per share after deducting any underwriters' discount and commission. Following the offering and Regeneron's $5B share repurchase, and assuming that the underwriters exercise their option to purchase additional shares in full, Sanofi will have disposed of all of its shares, other than 400,000 shares it intends to retain. 3. The impact of COVID-19 hasn't been evenly felt among the nation's retailers, with the biggest and strongest not just surviving, but thriving, while many smaller store chains and mom-and-pop shops face disaster, Teresa Rivas wrote in this week's edition of Barron's. In the past five years, the rise of e-commerce has changed the retail industry, tilting the landscape in favor of behemoths such as Amazon (AMZN) and Walmart (WMT) that can afford slick websites and fast, free delivery service, the author noted. Now, without a vaccine or effective treatment for coronavirus available near-term, these well-capitalized companies are likely to keep gobbling up market share at the expense of smaller operators, Rivas contended. 4. Novavax (NVAX) announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology. NVX-CoV2373 includes Novavax' proprietary Matrix-M adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies. Preliminary immunogenicity and safety results from the Phase 1 portion of the trial are expected in July 2020. The Phase 1/2 clinical trial is being conducted in two parts. The Phase 1 portion is a randomized, observer-blinded, placebo-controlled trial designed to evaluate the immunogenicity and safety of NVX-CoV2373, both adjuvanted with Matrix-M and unadjuvanted. The trial is enrolling approximately 130 healthy participants 18 to 59 years of age at two sites in Australia. The protocol's two-dose trial regimen assesses two dose sizes with Matrix-M and without. The Phase 2 portion is expected to be conducted in multiple countries, including the United States, and would assess immunity, safety and COVID-19 disease reduction in a broader age range. This Phase 1/2 approach allows for rapid advancement of NVX-CoV2373 during the pandemic. The trial is being supported by the recently announced funding arrangement with the Coalition for Epidemic Preparedness Innovations. 5. Winnebago Industries (WGO), Pool Cor. (POOL), Yeti (YETI) and DropBox (DBX) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
HTZ Hertz
$2.84 /

-0.215 (-7.04%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

AMZN Amazon.com
$2,435.90 /

-11.65 (-0.48%)

WMT Walmart
$124.32 /

-0.64 (-0.51%)

NVAX Novavax
$46.14 /

-3.975 (-7.93%)

WGO Winnebago
$58.06 /

+0.47 (+0.82%)

POOL Pool Corp.
$238.08 /

-0.32 (-0.13%)

YETI Yeti
$30.41 /

+0.38 (+1.27%)

DBX Dropbox
$21.67 /

-0.465 (-2.10%)

HTZ Hertz
$2.84 /

-0.215 (-7.04%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
REGN Regeneron
$569.94 /

+8.55 (+1.52%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
05/06/20 Oppenheimer
Regeneron price target raised to $625 from $525 at Oppenheimer
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
04/28/20 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
AMZN Amazon.com
$2,435.90 /

-11.65 (-0.48%)

05/18/20 Bernstein
Amazon not building standalone overnight network, says Bernstein
05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
05/12/20 Barrington
Amazon interest in AMC 'not outside the realm of possibility,' says Barrington
05/11/20 B. Riley FBR
Amazon buyout may not appeal to AMC shareholders, says B. Riley FBR
WMT Walmart
$124.32 /

-0.64 (-0.51%)

05/21/20 Bernstein
Walmart built for crisis, investing despite uncertainty, says Bernstein
05/20/20 Credit Suisse
Walmart price target raised to $135 from $127 at Credit Suisse
05/20/20 Guggenheim
Walmart price target raised to $140 from $135 at Guggenheim
05/20/20 Deutsche Bank
Walmart price target raised to $139 from $134 at Deutsche Bank
NVAX Novavax
$46.14 /

-3.975 (-7.93%)

05/18/20 B. Riley FBR
Novavax price target raised to $53 from $43 at B. Riley FBR
05/14/20 Ladenburg
Novavax price target raised to $50 from $38 at Ladenburg
05/12/20 B. Riley FBR
Novavax price target raised to $43 from $29 at B. Riley FBR
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
WGO Winnebago
$58.06 /

+0.47 (+0.82%)

05/12/20 SunTrust
Winnebago price target raised to $60 from $45 at SunTrust
04/17/20 Wolfe Research
Winnebago initiated with a Peer Perform at Wolfe Research
03/26/20 SunTrust
Winnebago price target raised to $38 from $28 at SunTrust
01/27/20 KeyBanc
Winnebago initiated with an Overweight at KeyBanc
POOL Pool Corp.
$238.08 /

-0.32 (-0.13%)

05/19/20 KeyBanc
Pool Corp. price target raised to $250 from $225 at KeyBanc
05/19/20 KeyBanc
Pool Corp. price target raised to $250 from $225 at KeyBanc
05/18/20 William Blair
Pool Corp. remains 'favorite safety stock' at William Blair
04/17/20 Sidoti
Pool Corp. downgraded to Neutral from Buy at Sidoti
YETI Yeti
$30.41 /

+0.38 (+1.27%)

05/05/20 Piper Sandler
Yeti price target lowered to $34 from $50 at Piper Sandler
04/28/20 BTIG
Yeti initiated with a Buy at BTIG
04/17/20 Stifel
Yeti downgraded to Hold from Buy at Stifel
04/15/20
Fly Intel: Top five analyst downgrades
DBX Dropbox
$21.67 /

-0.465 (-2.10%)

05/15/20 Gordon Haskett
Gordon Haskett points to possible signs of activism at Dropbox, McKesson
05/15/20 Citi
Dropbox initiated with a Buy at Citi
05/08/20 Jefferies
Dropbox price target raised to $22 from $20 at Jefferies
03/26/20 Goldman Sachs
Dropbox downgraded to Sell from Neutral at Goldman Sachs
HTZ Hertz
$2.84 /

-0.215 (-7.04%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

AMZN Amazon.com
$2,435.90 /

-11.65 (-0.48%)

WMT Walmart
$124.32 /

-0.64 (-0.51%)

NVAX Novavax
$46.14 /

-3.975 (-7.93%)

WGO Winnebago
$58.06 /

+0.47 (+0.82%)

POOL Pool Corp.
$238.08 /

-0.32 (-0.13%)

YETI Yeti
$30.41 /

+0.38 (+1.27%)

DBX Dropbox
$21.67 /

-0.465 (-2.10%)

HTZ Hertz
$2.84 /

-0.215 (-7.04%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

AMZN Amazon.com
$2,435.90 /

-11.65 (-0.48%)

WMT Walmart
$124.32 /

-0.64 (-0.51%)

NVAX Novavax
$46.14 /

-3.975 (-7.93%)

WGO Winnebago
$58.06 /

+0.47 (+0.82%)

POOL Pool Corp.
$238.08 /

-0.32 (-0.13%)

YETI Yeti
$30.41 /

+0.38 (+1.27%)

DBX Dropbox
$21.67 /

-0.465 (-2.10%)

HTZ Hertz
$2.84 /

-0.215 (-7.04%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

AMZN Amazon.com
$2,435.90 /

-11.65 (-0.48%)

WMT Walmart
$124.32 /

-0.64 (-0.51%)

NVAX Novavax
$46.14 /

-3.975 (-7.93%)

WGO Winnebago
$58.06 /

+0.47 (+0.82%)

YETI Yeti
$30.41 /

+0.38 (+1.27%)

DBX Dropbox
$21.67 /

-0.465 (-2.10%)

HTZ Hertz
$2.84 /

-0.215 (-7.04%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

AMZN Amazon.com
$2,435.90 /

-11.65 (-0.48%)

WMT Walmart
$124.32 /

-0.64 (-0.51%)

NVAX Novavax
$46.14 /

-3.975 (-7.93%)

YETI Yeti
$30.41 /

+0.38 (+1.27%)

DBX Dropbox
$21.67 /

-0.465 (-2.10%)

AMZN Amazon.com
$2,435.90 /

-11.65 (-0.48%)

Upgrade
Emerald Holding upgraded to Buy from Neutral at Goldman Sachs » 19:46
05/25/20
05/25
19:46
05/25/20
19:46
EEX

Emerald Holding

$2.00 /

+0.09 (+4.71%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EEX Emerald Holding
$2.00 /

+0.09 (+4.71%)

EEX Emerald Holding
$2.00 /

+0.09 (+4.71%)

03/19/20 Barclays
Emerald Holding downgraded to Equal Weight from Overweight at Barclays
03/17/20
Fly Intel: Top five analyst downgrades
03/17/20 Goldman Sachs
Emerald Holding downgraded to Neutral from Buy at Goldman Sachs
08/21/19
Fly Intel: Top five analyst upgrades
EEX Emerald Holding
$2.00 /

+0.09 (+4.71%)

Initiation
Gamida Cell initiated with an Overweight at Piper Sandler » 18:25
05/25/20
05/25
18:25
05/25/20
18:25
GMDA

Gamida Cell

$5.25 /

+0.39 (+8.02%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GMDA Gamida Cell
$5.25 /

+0.39 (+8.02%)

GMDA Gamida Cell
$5.25 /

+0.39 (+8.02%)

05/12/20 Oppenheimer
Gamida's omidubicel results 'potentially paradigm-changing,' says Oppenheimer
05/12/20 Oppenheimer
Gamida Cell price target raised to $20 from $18 at Oppenheimer
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 H.C. Wainwright
Gamida Cell initiated with a Buy at H.C. Wainwright
GMDA Gamida Cell
$5.25 /

+0.39 (+8.02%)

GMDA Gamida Cell
$5.25 /

+0.39 (+8.02%)

Periodicals
NIH says Gilead drug works best in COVID patients on oxygen, Reuters reports » 18:21
05/25/20
05/25
18:21
05/25/20
18:21
GILD

Gilead

$73.31 /

-0.17 (-0.23%)

The U.S. National…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GILD Gilead
$73.31 /

-0.17 (-0.23%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/21/20 JPMorgan
Gilead Phase 3 ulcerative colitis study 'mixed at best,' says JPMorgan
05/13/20 Piper Sandler
KOL sees remdesivir as COVID-19 standard of care, says Piper Sandler
05/13/20 JPMorgan
Gilead already given 'ample market credit' for remdesivir, says JPMorgan
GILD Gilead
$73.31 /

-0.17 (-0.23%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

Periodicals
U.S. accuses China of blocking flights, demands action, Reuters reports » 18:19
05/25/20
05/25
18:19
05/25/20
18:19
ALK

Alaska Air

$31.03 /

-0.79 (-2.48%)

, LUV

Southwest

$28.88 /

-0.71 (-2.40%)

, DAL

Delta Air Lines

$22.68 /

-0.47 (-2.03%)

, JBLU

JetBlue

$9.24 /

-0.2 (-2.12%)

, UAL

United Airlines

$25.40 /

-0.45 (-1.74%)

, SAVE

Spirit Airlines

$10.17 /

+0.09 (+0.89%)

, AAL

American Airlines

$9.70 /

-0.175 (-1.77%)

The U.S. government has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALK Alaska Air
$31.03 /

-0.79 (-2.48%)

LUV Southwest
$28.88 /

-0.71 (-2.40%)

DAL Delta Air Lines
$22.68 /

-0.47 (-2.03%)

JBLU JetBlue
$9.24 /

-0.2 (-2.12%)

UAL United Airlines
$25.40 /

-0.45 (-1.74%)

SAVE Spirit Airlines
$10.17 /

+0.09 (+0.89%)

AAL American Airlines
$9.70 /

-0.175 (-1.77%)

ALK Alaska Air
$31.03 /

-0.79 (-2.48%)

05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
Alaska Air price target lowered to $35 from $44 at Barclays
04/21/20 Deutsche Bank
Alaska Air price target lowered to $45 from $52 at Deutsche Bank
04/12/20
Airlines want Treasury to scrap proposal to make grant repayable, Reuters says
LUV Southwest
$28.88 /

-0.71 (-2.40%)

05/19/20 Goldman Sachs
Southwest, United seeing modest improvements in demand, says Goldman Sachs
05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
Southwest price target lowered to $35 from $40 at Barclays
04/30/20
Fly Intel: Top five analyst upgrades
DAL Delta Air Lines
$22.68 /

-0.47 (-2.03%)

05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
Delta Air Lines downgraded to Equal Weight from Overweight at Barclays
04/23/20 Raymond James
Delta Air Lines price target lowered to $36 from $40 at Raymond James
04/21/20 Deutsche Bank
Delta Air Lines price target lowered to $47 from $51 at Deutsche Bank
JBLU JetBlue
$9.24 /

-0.2 (-2.12%)

05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
JetBlue price target lowered to $11 from $16 at Barclays
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 Susquehanna
JetBlue downgraded to Neutral at Susquehanna
UAL United Airlines
$25.40 /

-0.45 (-1.74%)

05/19/20 Goldman Sachs
Southwest, United seeing modest improvements in demand, says Goldman Sachs
05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
United Airlines price target lowered to $40 from $60 at Barclays
04/23/20 Citi
Citi cuts United Airlines target, opens 'negative 30-day catalyst watch'
SAVE Spirit Airlines
$10.17 /

+0.09 (+0.89%)

05/18/20 Evercore ISI
Spirit Airlines upgraded to Outperform from In Line at Evercore ISI
05/13/20
Fly Intel: Top five analyst downgrades
05/13/20 Raymond James
Spirit Airlines downgraded to Market Perform from Outperform at Raymond James
05/13/20 Citi
Citi opens positive '90-day catalyst watch' on Spirit despite target cut
AAL American Airlines
$9.70 /

-0.175 (-1.77%)

05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
American Airlines downgraded to Underweight from Equal Weight at Barclays
05/01/20 Evercore ISI
American Airlines price target lowered to $1 from $10 at Evercore ISI
04/27/20 Citi
American Airlines price target lowered to $10 from $13 at Citi
ALK Alaska Air
$31.03 /

-0.79 (-2.48%)

LUV Southwest
$28.88 /

-0.71 (-2.40%)

DAL Delta Air Lines
$22.68 /

-0.47 (-2.03%)

JBLU JetBlue
$9.24 /

-0.2 (-2.12%)

UAL United Airlines
$25.40 /

-0.45 (-1.74%)

SAVE Spirit Airlines
$10.17 /

+0.09 (+0.89%)

AAL American Airlines
$9.70 /

-0.175 (-1.77%)

ALK Alaska Air
$31.03 /

-0.79 (-2.48%)

LUV Southwest
$28.88 /

-0.71 (-2.40%)

DAL Delta Air Lines
$22.68 /

-0.47 (-2.03%)

JBLU JetBlue
$9.24 /

-0.2 (-2.12%)

UAL United Airlines
$25.40 /

-0.45 (-1.74%)

SAVE Spirit Airlines
$10.17 /

+0.09 (+0.89%)

AAL American Airlines
$9.70 /

-0.175 (-1.77%)

ALK Alaska Air
$31.03 /

-0.79 (-2.48%)

LUV Southwest
$28.88 /

-0.71 (-2.40%)

DAL Delta Air Lines
$22.68 /

-0.47 (-2.03%)

JBLU JetBlue
$9.24 /

-0.2 (-2.12%)

UAL United Airlines
$25.40 /

-0.45 (-1.74%)

SAVE Spirit Airlines
$10.17 /

+0.09 (+0.89%)

AAL American Airlines
$9.70 /

-0.175 (-1.77%)

ALK Alaska Air
$31.03 /

-0.79 (-2.48%)

LUV Southwest
$28.88 /

-0.71 (-2.40%)

DAL Delta Air Lines
$22.68 /

-0.47 (-2.03%)

JBLU JetBlue
$9.24 /

-0.2 (-2.12%)

UAL United Airlines
$25.40 /

-0.45 (-1.74%)

SAVE Spirit Airlines
$10.17 /

+0.09 (+0.89%)

AAL American Airlines
$9.70 /

-0.175 (-1.77%)

Periodicals
White House limits travel to U.S. from Brazil due to COVID, Reuters says » 18:14
05/25/20
05/25
18:14
05/25/20
18:14
SPY

SPDR S&P 500 ETF Trust

$295.47 /

+0.69 (+0.23%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

The White House announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$295.47 /

+0.69 (+0.23%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$295.47 /

+0.69 (+0.23%)

03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
12/16/19 Piper Sandler
Piper establishes 2020 S&P 500 price objective of 3,600
SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$295.47 /

+0.69 (+0.23%)

SPY SPDR S&P 500 ETF Trust
$295.47 /

+0.69 (+0.23%)

SPY SPDR S&P 500 ETF Trust
$295.47 /

+0.69 (+0.23%)

SPY SPDR S&P 500 ETF Trust
$295.47 /

+0.69 (+0.23%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$295.47 /

+0.69 (+0.23%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Periodicals
Bayer makes progress in settlement talks over weedkiller, Reuters says » 18:10
05/25/20
05/25
18:10
05/25/20
18:10
BAYRY

Bayer

$0.00 /

+ (+0.00%)

Bayer said on Monday it…

Bayer said on Monday it had made progress seeking a settlement over claims its glyphosate-based Roundup weedkiller causes cancer, Reuters' Ludwig Burger reports. The drugs and pesticides group is keen to draw a line under the legal dispute, which it inherited via its $63B takeover of Monsanto in 2018. In April, Bayer's management regained shareholder support for its handling of the litigation process. Reference Link

ShowHide Related Items >><<
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

Periodicals
Intesa to give preliminary green light to state-backed loan for FCA,Reuters says » 18:06
05/25/20
05/25
18:06
05/25/20
18:06
FCAU

Fiat Chrysler

$8.12 /

+0.075 (+0.93%)

Italian bank Intesa…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FCAU Fiat Chrysler
$8.12 /

+0.075 (+0.93%)

FCAU Fiat Chrysler
$8.12 /

+0.075 (+0.93%)

03/24/20 UBS
Tesla and BMW upgraded, Ford downgraded at UBS
03/11/20 Morgan Stanley
Morgan Stanley cuts estimates for GM, Ford and FCA on coronavirus 'demand shock'
12/18/19 Evercore ISI
Evercore ISI upgrades Fiat Chrysler to Outperform after Peugeot deal formalized
12/18/19 Evercore ISI
Fiat Chrysler upgraded to Outperform from In Line at Evercore ISI
FCAU Fiat Chrysler
$8.12 /

+0.075 (+0.93%)

FCAU Fiat Chrysler
$8.12 /

+0.075 (+0.93%)

FCAU Fiat Chrysler
$8.12 /

+0.075 (+0.93%)

FCAU Fiat Chrysler
$8.12 /

+0.075 (+0.93%)

Periodicals
Daimler forges ahead with electric flagship sedan plans, Bloomberg says » 18:03
05/25/20
05/25
18:03
05/25/20
18:03
DDAIF

Daimler AG

$0.00 /

+ (+0.00%)

Daimler AG is pushing…

Daimler AG is pushing ahead with plans to produce an all-electric version of its flagship Mercedes S-Class sedan from next year even as it cuts back in other areas to weather a slump in demand across the industry, Bloomberg's Christoph Rauwald reports. The company's main Mercedes-Benz cars unit aims to make all of its factories CO2-neutral by the end of 2022, Chief Executive Officer Ola Kallenius said Monday in a webcast. Reference Link

ShowHide Related Items >><<
DDAIF Daimler AG
$0.00 /

+ (+0.00%)

DDAIF Daimler AG
$0.00 /

+ (+0.00%)

05/04/20 RBC Capital
Daimler AG price target raised to EUR 42 from EUR 39 at RBC Capital
04/30/20 JPMorgan
Daimler AG price target raised to EUR 45 from EUR 29 at JPMorgan
03/30/20 Exane BNP Paribas
Daimler AG downgraded to Underperform from Neutral at Exane BNP Paribas
03/26/20 Kepler Cheuvreux
Daimler AG upgraded to Buy from Hold at Kepler Cheuvreux
DDAIF Daimler AG
$0.00 /

+ (+0.00%)

DDAIF Daimler AG
$0.00 /

+ (+0.00%)

DDAIF Daimler AG
$0.00 /

+ (+0.00%)

Periodicals
WHO's hydroxychloroquine trial suspended pending safety data, Bloomberg says » 18:00
05/25/20
05/25
18:00
05/25/20
18:00
MYL

Mylan

$15.63 /

-0.37 (-2.31%)

, TEVA

Teva

$11.97 /

-0.05 (-0.42%)

, NVS

Novartis

$84.84 /

-0.12 (-0.14%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

The World Health…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

03/25/20 Cantor Fitzgerald
Few concerns weighing on Mylan shares today, says Cantor Fitzgerald
02/06/20 BMO Capital
Biogen price target raised to $317 from $297 at BMO Capital
02/05/20 Baird
Biogen price target raised to $290 from $250 at Baird
02/05/20 Mizuho
Biogen's Tecfidera win worth $15-$30 per share to DCF, Mizuho says
TEVA Teva
$11.97 /

-0.05 (-0.42%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
NVS Novartis
$84.84 /

-0.12 (-0.14%)

05/18/20 Jefferies
Jefferies names Beazley, Ferguson, Novartis, Rio Tinto high conviction ideas
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
BAYRY Bayer
$0.00 /

+ (+0.00%)

04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

NVS Novartis
$84.84 /

-0.12 (-0.14%)

MYL Mylan
$15.63 /

-0.37 (-2.31%)

Periodicals
German court orders Volkswagen to compensate customers, WSJ reports » 17:56
05/25/20
05/25
17:56
05/25/20
17:56
VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

Germany's highest…

Germany's highest civil court ruled against Volkswagen in the first case brought by customers seeking damages in connection with the car maker's emissions-cheating scandal, a landmark ruling that could herald further litigation against Volkswagen and some competitors, The Wall Street Journal's William Boston reports. Monday's ruling comes more than four years after Volkswagen in 2015 admitted to installing illegal software on millions of diesel models, the author notes. The device allowed the cars to pass emissions tests in the laboratory while emitting much higher levels of toxic pollutants during normal road use. Reference Link

ShowHide Related Items >><<
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

04/30/20 JPMorgan
Volkswagen price target raised to EUR 150 from EUR 116 at JPMorgan
03/26/20 RBC Capital
Volkswagen price target raised to EUR 175 from EUR 165 at RBC Capital
03/17/20 Baird
Baird says 'great opportunity' to get back involved with Navistar
03/09/20 Cowen
Cowen upgrades Paccar to Market Perform on 'flight to quality'
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

Periodicals
Germany, Lufthansa agree on $9.8B bailout, WSJ reports » 17:54
05/25/20
05/25
17:54
05/25/20
17:54
DLAKY

Lufthansa

$0.00 /

+ (+0.00%)

The German government and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DLAKY Lufthansa
$0.00 /

+ (+0.00%)

DLAKY Lufthansa
$0.00 /

+ (+0.00%)

05/06/20 HSBC
Lufthansa downgraded to Reduce from Hold at HSBC
04/24/20 Barclays
Lufthansa price target lowered to EUR 6.20 from EUR 12.70 at Barclays
04/24/20 Societe Generale
Lufthansa double downgraded to Sell at Societe Generale
04/24/20 Societe Generale
Lufthansa downgraded to Sell from Buy at Societe Generale
DLAKY Lufthansa
$0.00 /

+ (+0.00%)

DLAKY Lufthansa
$0.00 /

+ (+0.00%)

Periodicals
USB creates new global financing team, Reuters reports » 17:52
05/25/20
05/25
17:52
05/25/20
17:52
UBS

UBS

$9.82 /

-0.2 (-2.00%)

UBS said on Monday it has…

UBS said on Monday it has created a new global financing team, a group that will span across divisions under one group in order to serve clients in a faster and simpler fashion, Reuters' Chuck Mikolajczak reports. The new team will be led by Remi Mennesson, who will join the Swiss lender in November 2020, and report to the company's four co-presidents, said a memo seen by Reuters and confirmed by the bank. Reference Link

ShowHide Related Items >><<
UBS UBS
$9.82 /

-0.2 (-2.00%)

UBS UBS
$9.82 /

-0.2 (-2.00%)

05/06/20 Deutsche Bank
UBS price target raised to CHF 10 from CHF 9 at Deutsche Bank
05/04/20 Morgan Stanley
UBS price target raised to CHF 11 from CHF 10 at Morgan Stanley
05/04/20 Berenberg
UBS downgraded to Hold from Buy at Berenberg
04/29/20 RBC Capital
UBS price target raised to CHF 11 from CHF 10 at RBC Capital
UBS UBS
$9.82 /

-0.2 (-2.00%)

UBS UBS
$9.82 /

-0.2 (-2.00%)

UBS UBS
$9.82 /

-0.2 (-2.00%)

Periodicals
Toyota, Nissan, Honda gear up for Mexico reboot, Reuters reports » 17:49
05/25/20
05/25
17:49
05/25/20
17:49
TM

Toyota

$117.51 /

-0.655 (-0.55%)

, NSANY

Nissan

$0.00 /

+ (+0.00%)

, HMC

Honda

$23.60 /

-0.11 (-0.46%)

Toyota (TM), Nissan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TM Toyota
$117.51 /

-0.655 (-0.55%)

NSANY Nissan
$0.00 /

+ (+0.00%)

HMC Honda
$23.60 /

-0.11 (-0.46%)

TM Toyota
$117.51 /

-0.655 (-0.55%)

03/30/20 UBS
Toyota and Honda upgraded to Buy, Nissan cut to Sell at UBS
03/30/20 UBS
Toyota upgraded to Buy from Neutral at UBS
02/26/20
Fly Intel: Top five analyst downgrades
02/26/20 JPMorgan
Toyota downgraded to Neutral from Overweight at JPMorgan
NSANY Nissan
$0.00 /

+ (+0.00%)

03/30/20 UBS
Nissan downgraded to Sell from Buy at UBS
01/02/20 Evercore ISI
Renault downgraded to Underperform from In Line at Evercore ISI
06/05/19 UBS
Nissan upgraded to Buy from Sell at UBS
HMC Honda
$23.60 /

-0.11 (-0.46%)

05/12/20 CLSA
Honda downgraded to Underperform from Outperform at CLSA
04/13/20 Goldman Sachs
Honda upgraded to Buy from Neutral at Goldman Sachs
03/30/20 UBS
Honda upgraded to Buy from Neutral at UBS
TM Toyota
$117.51 /

-0.655 (-0.55%)

HMC Honda
$23.60 /

-0.11 (-0.46%)

TM Toyota
$117.51 /

-0.655 (-0.55%)

NSANY Nissan
$0.00 /

+ (+0.00%)

HMC Honda
$23.60 /

-0.11 (-0.46%)

TM Toyota
$117.51 /

-0.655 (-0.55%)

NSANY Nissan
$0.00 /

+ (+0.00%)

HMC Honda
$23.60 /

-0.11 (-0.46%)

Periodicals
Volkswagen Mexico not talking of restart with state decree in place,Reuters says » 17:47
05/25/20
05/25
17:47
05/25/20
17:47
VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

Volkswagen said it had…

Volkswagen said it had satisfied federal requirements to resume production in Mexico but would not make announcements about renewing operations as long as a decree in the state of Puebla remains in effect, Reuters' Sharay Angulo reports. Reference Link

ShowHide Related Items >><<
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

04/30/20 JPMorgan
Volkswagen price target raised to EUR 150 from EUR 116 at JPMorgan
03/26/20 RBC Capital
Volkswagen price target raised to EUR 175 from EUR 165 at RBC Capital
03/17/20 Baird
Baird says 'great opportunity' to get back involved with Navistar
03/09/20 Cowen
Cowen upgrades Paccar to Market Perform on 'flight to quality'
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

Periodicals
Minister says Germany still in talks over Lufthansa bailout, Reuters reports » 17:40
05/25/20
05/25
17:40
05/25/20
17:40
DLAKY

Lufthansa

$0.00 /

+ (+0.00%)

Germany is still in talks…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DLAKY Lufthansa
$0.00 /

+ (+0.00%)

DLAKY Lufthansa
$0.00 /

+ (+0.00%)

05/06/20 HSBC
Lufthansa downgraded to Reduce from Hold at HSBC
04/24/20 Barclays
Lufthansa price target lowered to EUR 6.20 from EUR 12.70 at Barclays
04/24/20 Societe Generale
Lufthansa double downgraded to Sell at Societe Generale
04/24/20 Societe Generale
Lufthansa downgraded to Sell from Buy at Societe Generale
DLAKY Lufthansa
$0.00 /

+ (+0.00%)

DLAKY Lufthansa
$0.00 /

+ (+0.00%)

Conference/Events
EverQuote participates in a conference call with Canaccord Genuity » 17:24
05/25/20
05/25
17:24
05/25/20
17:24
EVER

EverQuote

$49.00 /

-0.24 (-0.49%)

Internet Analyst Graham…

Internet Analyst Graham holds a conference call with management on May 26 at 11 am hosted by Canaccord Genuity. Webcast Link

ShowHide Related Items >><<
EVER EverQuote
$49.00 /

-0.24 (-0.49%)

EVER EverQuote
$49.00 /

-0.24 (-0.49%)

05/05/20 Needham
EverQuote price target raised to $55 from $45 at Needham
05/05/20 Canaccord
EverQuote price target raised to $50 from $48 at Canaccord
02/27/20 JMP Securities
EverQuote price target raised to $50 from $35 at JMP Securities
02/26/20 BofA
EverQuote downgraded to Neutral from Buy at BofA
EVER EverQuote
$49.00 /

-0.24 (-0.49%)

EVER EverQuote
$49.00 /

-0.24 (-0.49%)

EVER EverQuote
$49.00 /

-0.24 (-0.49%)

EVER EverQuote
$49.00 /

-0.24 (-0.49%)

Hot Stocks
Novavax initiates Phase 1/2 clinical trial of COVID-19 vaccine » 17:02
05/25/20
05/25
17:02
05/25/20
17:02
NVAX

Novavax

$46.14 /

-3.975 (-7.93%)

Novavax announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NVAX Novavax
$46.14 /

-3.975 (-7.93%)

NVAX Novavax
$46.14 /

-3.975 (-7.93%)

05/18/20 B. Riley FBR
Novavax price target raised to $53 from $43 at B. Riley FBR
05/14/20 Ladenburg
Novavax price target raised to $50 from $38 at Ladenburg
05/12/20 B. Riley FBR
Novavax price target raised to $43 from $29 at B. Riley FBR
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
NVAX Novavax
$46.14 /

-3.975 (-7.93%)

NVAX Novavax
$46.14 /

-3.975 (-7.93%)

NVAX Novavax
$46.14 /

-3.975 (-7.93%)

NVAX Novavax
$46.14 /

-3.975 (-7.93%)

Hot Stocks
Village Farms' Pure Sunfarms to being roll out of vape products this summer » 16:59
05/25/20
05/25
16:59
05/25/20
16:59
VFF

Village Farms

$5.19 /

+0.94 (+22.12%)

Village Farms announced…

Village Farms announced that its majority-owned joint venture for large-scale, low-cost cannabis production, Pure Sunfarms, has received from Health Canada its cannabis cultivation sales license based on an initial production area within its second 1.1M square foot greenhouse facility in Delta, British Columbia, allowing it to expand capacity as needed through successive license amendments. The Delta 2 facility is located adjacent to the 1.1M square foot Delta 3 greenhouse facility and when in production, is expected to contribute to further lowering Pure Sunfarms' cost of cultivation. Pure Sunfarms is now preparing to begin the roll out of its first bottled cannabis oils, as well as its first Cannabis 2.0 offerings this summer. Pure Sunfarms' Cannabis 2.0 roll out will begin with the launch of a selection of pre-filled 510 vape cartridges, available in the extract forms of its dried cannabis strains, as well as a selection of disposable vape pens - all under the Pure Sunfarms brand.

ShowHide Related Items >><<
VFF Village Farms
$5.19 /

+0.94 (+22.12%)

VFF Village Farms
$5.19 /

+0.94 (+22.12%)

05/19/20 Stifel
Village Farms price target lowered to C$15 from C$20 at Stifel
04/02/20 Craig-Hallum
Village Farms price target lowered to $10 from $15 at Craig-Hallum
04/02/20 Roth Capital
Village Farms price target lowered to $10 from $16 at Roth Capital
02/11/20 Craig-Hallum
Village Farms price target lowered to $15 from $20 at Craig-Hallum
VFF Village Farms
$5.19 /

+0.94 (+22.12%)

Hot Stocks
Vermilion Energy announces CEO departure, appoints new President » 16:49
05/25/20
05/25
16:49
05/25/20
16:49
VET

Vermilion Energy

$5.10 /

-0.145 (-2.76%)

Vermilion Energy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VET Vermilion Energy
$5.10 /

-0.145 (-2.76%)

VET Vermilion Energy
$5.10 /

-0.145 (-2.76%)

05/21/20 CIBC
Vermilion Energy price target raised to C$7 from C$6 at CIBC
04/30/20 CIBC
Vermilion Energy upgraded to Neutral from Underperformer at CIBC
04/23/20 National Bank
Vermilion Energy upgraded to Sector Perform from Underperform at National Bank
03/25/20 Credit Suisse
Vermilion Energy price target lowered to C$5 from C$23 at Credit Suisse
VET Vermilion Energy
$5.10 /

-0.145 (-2.76%)

VET Vermilion Energy
$5.10 /

-0.145 (-2.76%)

Hot Stocks
Teva presents data evaluating AJOVY experience in difficult-to-treat migraine » 16:38
05/25/20
05/25
16:38
05/25/20
16:38
TEVA

Teva

$11.97 /

-0.05 (-0.42%)

Teva Pharmaceutical…

Teva Pharmaceutical presented a wide range of important new data on AJOVY and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials, which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Pooled analyses of the Phase 3 FOCUS, HALO-EM and HALO-CM clinical trials in patients 60 years of age or older with EM or CM, examined treatment with fremanezumab versus placebo over 12 weeks. Reductions from baseline in monthly migraine days, headache days of at least moderate severity, and days with acute headache medication use over 12 weeks were significantly greater with quarterly and monthly fremanezumab versus placebo. The analyses also examined early onset of efficacy and improved headache-related disability, health-related quality-of-life, productivity, and satisfaction in this patient population. Additionally, the analyses looked at cardiovascular adverse events in fremanezumab and placebo treated patients in this group, regardless of whether or not they had a cardiovascular medical history. Additional pooled analyses of the Phase 3 trials were also conducted to examine cardiovascular safety across all patients. The analyses were performed in migraine patients with cardiovascular/cerebrovascular risk factors. The overall incidence of cardiovascular adverse events in these patients were low and comparable between fremanezumab and placebo treated groups. An increase in the number of risk factors did not seem to correlate with an increase in frequency of cardiac and vascular adverse events. Additionally, the analyses examined patients with migraine using cardiovascular medications at baseline, and patients using concomitant triptans with those who did not use triptans. Similar to the overall trial populations, the most common adverse events reported in all of these subgroups were injection site reactions. Two analyses evaluated the economic and disease burden of migraine across patients in the United Kingdom, France and Spain. The first analysis found that CM patients experienced greater disability caused by migraine versus EM patients. CM patients also reported lower health status than EM patients for their most recent migraine. The second evaluation, which included examining electronic medical records from 84,266 adult patients with EM and CM, found CM patients had more migraine-related consultations with their general practitioners than EM patients. Additionally, average quarterly treatment costs were higher for CM patients in all three countries. These results point to substantial migraine disability and unmet treatment needs across the three countries. They also associate migraine with a significant healthcare and economic burden that includes higher costs for CM patients.

ShowHide Related Items >><<
TEVA Teva
$11.97 /

-0.05 (-0.42%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
TEVA Teva
$11.97 /

-0.05 (-0.42%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

TEVA Teva
$11.97 /

-0.05 (-0.42%)

Hot Stocks
Churchill Downs, Aristocrat announce agreement in principle to settle lawsuits » 16:33
05/25/20
05/25
16:33
05/25/20
16:33
CHDN

Churchill Downs

$122.35 /

+4.15 (+3.51%)

, ARLUF

Aristocrat Leisure

$0.00 /

+ (+0.00%)

Churchill Downs (CHDN)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CHDN Churchill Downs
$122.35 /

+4.15 (+3.51%)

CHDN Churchill Downs
$122.35 /

+4.15 (+3.51%)

04/06/20 Jefferies
Eldorado has 'considerable upside' from Caesars merger, says Jefferies
03/02/20 JPMorgan
Golden Entertainment downgraded to Neutral on downside risk at JPMorgan
03/02/20 JPMorgan
JPMorgan upgrades Churchill Downs on overblown COVID-19 concerns
03/02/20 JPMorgan
Churchill Downs upgraded to Overweight from Neutral at JPMorgan
ARLUF Aristocrat Leisure
$0.00 /

+ (+0.00%)

03/29/20 Goldman Sachs
Aristocrat Leisure upgraded to Buy from Neutral at Goldman Sachs
03/02/20 Credit Suisse
Aristocrat Leisure upgraded to Outperform from Neutral at Credit Suisse
10/28/19 Credit Suisse
Aristocrat Leisure downgraded to Neutral from Outperform at Credit Suisse
CHDN Churchill Downs
$122.35 /

+4.15 (+3.51%)

CHDN Churchill Downs
$122.35 /

+4.15 (+3.51%)

Hot Stocks
Regeneron to repurchase $5B of shares directly from Sanofi » 13:49
05/25/20
05/25
13:49
05/25/20
13:49
REGN

Regeneron

$569.94 /

+8.55 (+1.52%)

, SNY

Sanofi

$47.31 /

-0.18 (-0.38%)

Regeneron Pharmaceuticals…

Regeneron Pharmaceuticals (REGN) announced that subject to and immediately following the close of its secondary offering, Regeneron agreed to repurchase approximately $5B of common stock directly from Sanofi (SNY). The purchase price to be paid by Regeneron will be equal to the net offering price per share after deducting any underwriters' discount and commission. Regeneron will fund the purchase with a combination of $3.5B of cash on hand and $1.5 billion of fully-committed bridge financing from Goldman Sachs Bank USA.

ShowHide Related Items >><<
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
05/06/20 Oppenheimer
Regeneron price target raised to $625 from $525 at Oppenheimer
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
04/28/20 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

Syndicate
Regeneron announces secondary offering for Sanofi sale of 12.8M shares » 13:48
05/25/20
05/25
13:48
05/25/20
13:48
REGN

Regeneron

$569.94 /

+8.55 (+1.52%)

, SNY

Sanofi

$47.31 /

-0.18 (-0.38%)

Regeneron Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
05/06/20 Oppenheimer
Regeneron price target raised to $625 from $525 at Oppenheimer
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
04/28/20 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

Hot Stocks
Sanofi to sell investment in Regeneron, says will not impact collaboration » 13:45
05/25/20
05/25
13:45
05/25/20
13:45
REGN

Regeneron

$569.94 /

+8.55 (+1.52%)

, SNY

Sanofi

$47.31 /

-0.18 (-0.38%)

Sanofi (SNY) announced…

Sanofi (SNY) announced its intent to sell its equity investment in Regeneron Pharmaceuticals (REGN) through a registered public offering and related share repurchase by Regeneron. The registered offering and share repurchase will have no impact on the ongoing collaboration between Sanofi and Regeneron, the company said in a statement. A preliminary prospectus supplement relating to the offering of Regeneron's shares will be filed with the SEC. Sanofi currently holds approximately 23.2M shares of Regeneron's common stock, representing approximately 20.6% ownership. Regeneron has agreed to repurchase $5B of its stock from Sanofi conditional on completion of the proposed public offering. If the offering and repurchase are completed and the underwriters fully exercise their option to purchase additional shares, Sanofi will continue to own approximately 400,000 shares of Regeneron's common stock, which Sanofi is retaining in support of the ongoing collaboration with Regeneron. "Sanofi and Regeneron's collaboration has been one of the most productive in the industry, creating significant value for both companies but more importantly, resulting in five important medicines for patients. Sanofi remains committed to continuing our collaboration with Regeneron which remains an integral part of our overall strategy, and this decision was fully aligned with Regeneron, said Paul Hudson, Chief Executive Officer, Sanofi. "The decision to divest our holdings is consistent with our efforts to enhance value creation for our shareholders. We believe the proceeds from this transaction will help further our ability to execute on our strategy to drive innovation and growth."

ShowHide Related Items >><<
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
05/06/20 Oppenheimer
Regeneron price target raised to $625 from $525 at Oppenheimer
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
04/28/20 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

SNY Sanofi
$47.31 /

-0.18 (-0.38%)

REGN Regeneron
$569.94 /

+8.55 (+1.52%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.